A legal storm is brewing in Delaware’s federal court, where Factor Bioscience has taken aim at Cellectis and pharmaceutical heavyweight AstraZeneca. At the heart of the fight: who owns the cutting edge of gene-editing technology that could transform cancer treatment.
Factor claims its pioneering work with messenger RNA and protein-based TALENs—tools designed to reprogram cells to fight diseases like leukemia and lymphoma—was copied by France-based Cellectis. The alleged infringement, according to Factor, gave Cellectis an unfair springboard to create its own therapies, which were later tied to AstraZeneca through a licensing deal struck in 2023.
Cellectis has long provided its technology for AstraZeneca’s research in oncology, immunology, and rare diseases. But Factor’s lawsuit argues that this arrangement effectively roped AstraZeneca into violating its patent rights, putting the British pharma titan squarely in the legal crosshairs.
“If massive corporations can exploit the hard-won innovations of smaller companies unchecked, the future of breakthrough science itself is at risk,” warned Factor CEO Matt Angel.
The Cambridge, Massachusetts biotech is seeking damages—though it hasn’t put a number on the table. What is clear is the stakes: with billions tied to the race for next-generation genetic therapies, the courtroom may become the new battleground for the future of medicine.
The case has been filed as Factor Bioscience Inc. v. Cellectis Inc., U.S. District Court for the District of Delaware, No. 1:25-cv-01197.
